P1069 (DAIDS ID 10620): A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC) and Nevirapine (NVP) as GPO-VIR® Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children 5 Months to 13 Years
|Study Status||Study Restriction|
US & Non-US
What is P1069?
P1069 was a Phase I/II, two arm, randomized, open-label, multiple dose pharmacokinetic cross-over study. The study was designed to evaluate the safety and compare the bioavailability of ZDV, 3TC and NVP in the GPO-VIR® Z30 pediatric tablet formulation with the liquid formulations of ZDV, 3TC and NVP in HIV-infected children in Thailand and to estimate the population exposure to NVP delivered in the GPO-VIR® Z30 pediatric formulation, and to compare this exposure to an adult exposure of therapeutically adequate NVP concentration.
Sites where the study was implemented:
|CRS ID||Site Name||City||Country|
|No sites at this time.|
|No records returned.|